Hikma Pharmaceutical (HKMPF) 29.5000 $HKMPF Glo
Post# of 273249
Posted On: 08/21/2016 9:04:26 AM
Hikma Pharmaceutical (HKMPF) 29.5000 $HKMPF
Global Nerve Gas Auto-Injector Market Report 2016-2020 - Analysis, Technologies & Forecasts - Key Vendors: Baxter International, Hikma Pharmaceuticals, Hospira - Research and Markets
BusinessWire - Wed May 11, 9:30AM CDT
Research and Markets has announced the addition of the "Nerve Gas Auto-Injector Market" report to their offering.
BAX: 47.95 (-0.06)
Xellia Pharmaceuticals Expands US Production with Acquisition of Manufacturing Plant from Hikma Pharmaceuticals
BusinessWire - Wed Nov 25, 3:08AM CST
Xellia Pharmaceuticals ('Xellia'), a specialty pharmaceutical company focusing on providing important anti-infective treatments against serious and often life-threatening infections, has acquired manufacturing facilities in Bedford, Ohio from a wholly owned subsidiary of Hikma Pharmaceuticals PLC ('Hikma'). Financial details are not disclosed.
Global Biosimilars Market Report, 2015-2025 - The biosimilar market is projected to be worth USD 32 billion worldwide by 2025
PR Newswire Europe - Tue Nov 03, 11:11AM CST
Research and Markets (http://www.researchandmarkets.com/research/hcv3cc/global [http://www.researchandmarkets.com/research/hcv3cc/global]) has announced the addition of the "Global Biosimilars Market, 2015 - 2025" [http://www.researchandmarkets.com/research/hcv3cc/global] report to their offering.
BIIB: 316.81 (+3.43), UTHR: 126.92 (+1.30), CTIC: 0.35 (unch), CHRS: 30.51 (+0.37), JNJ: 119.92 (-0.80), NPSP: 45.97 (+0.01), IBIO: 0.66 (-0.01), EBS: 28.01 (+0.09), SLXP: 172.96 (+0.15), AMGN: 173.62 (-1.13), SPPI: 5.91 (-0.02), LLY: 79.06 (-0.72), GSK: 44.16 (-0.33), ANIK: 49.82 (+0.04), NVO: 46.88 (-0.16), BAX: 47.95 (-0.06), MRK: 63.36 (-0.27), NVS: 81.34 (-0.60)
Central Asia Business Daily Subscriptioon
M2 - Thu Oct 22, 3:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kmg769/central_asia) has announced the addition of the "Central Asia Business Daily " newsletter to their offering. The central Asia Business Daily, delivers all the business news of Central Asia companies/industries/economy that helps companies/investors to follow-up on new business opportunities of and among Central Asian countries such as Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan, and Uzbekistan and with rest of the world. The objective of this daily report is to comprehensively cover Central Asia business news daily and thereby help the investors in Central Asia and rest of the world to assess the investment trends and opportunities of Central Asia business. Key Features - Most-updated daily news coverage provided by the 24/7 news researchers at 3 global offices - Company news analysts with years of experience analyze business transactions and the investment trends every day for Central Asia to put together this Daily Report - Most of the available news resources comprehensively covered (including established news portals, reliable primary and secondary news sources, business media sites, company websites, press releases, and stock exchanges) - Original news source links provided for all news for further reference - For any incomplete news or information, assistance taken from the relevant officials/executives through e-mails/phone calls - This Daily Report is specifically designed to bring-out every day all the available news on the current business transactions, investment trends, business opportunities and helpful resources for pursuing Central Asian collaborations. Any other related query, analytical and research, is also furnished if needed Publication Frequency: Daily Key Topics Covered: Section 1: Business News of Each Central Asian Country Section 2: Business News among Central Asian Countries Section 3: International Business News with Central Asia Companies Mentioned - ATFBank JSC - Asian Development Bank - Asiana Airlines - Barqi Tojik - Beeline Uzbekistan LLC - Central Bank of Uzbekistan - Daewoo Group - Flynas Company LCC - GM Uzbekistan - Hikma Pharmaceuticals PL - INGO-Uzbekistan - Islamic Development Bank - KAZ Minerals PLC - Karachaganak Petroleum Operating B.V. - Kcell JSC - LG Electronics Inc. - Microsoft Kazakhstan - Nur Telecom - Pojazdy Szynowe PESA Bydgoszcz SA - Rio Tinto Group United Kingdom - Samruk-Kazyna National Welfare Fund JSC - Telecom Tajikistan - Tengizchevroil JSC - Thomson Reuters Corp. - Toyota Motor Corporation - Turkish Petroleum Corporation - Uzbekistan Airways - Uzbekneftegaz JSC - VimpelCom Ltd. - Vostok-geoldobycha OJSC For more information visit http://www.researchandmarkets.com/research/km...ntral_asia
VIP: 4.35 (unch), TM: 119.62 (+0.68), TRI: 41.61 (-0.27)
Basilea signs exclusive distribution agreement for Zevtera(r) (ceftobiprole medocaril) in the Middle East and North Africa with Hikma Pharmaceuticals LLC
GlobeNewswire - Thu Oct 15, 12:20AM CDT
-- Hikma to commercialize antibiotic Zevtera in the Middle East and North Africa (MENA) region
Jordan Pharmaceutical Market Study 2015
M2 - Fri Sep 25, 5:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5xfhgw/the) has announced the addition of the "The Pharmaceutical Market: Jordan" report to their offering. Overview Of The Pharmaceutical Market In Jordan: We expect that Jordan will continue to provide modest opportunities to research-based pharmaceutical manufacturers. In line with the authorities' efforts to expand healthcare insurance coverage , we envisage measures aiming to promote the use of cheaper generic medicines, in tandem with price-reduction strategies. Nevertheless, the expansion of government provision and the higher uptake of generic medicines will conspire to keep longer term growth steady , boosted by upward volume changes, with the patented drug market to continue to be supported by rising numbers of medical tourists. Risk/Reward Rating: Jordan's composite Pharmaceutical Risk/Reward Ratings score for Q1 remains unchanged in relation to the previous quarter. At 49.9 out of the maximum 100, Jordan is again ranked 10th, out of the 30 markets surveyed in the Middle East and Africa region. Jordan's rewards and risk scores remain evenly balanced, with both components standing firmly above the regional averages. Companies Mentioned - Dar al-Dawa - GlaxoSmithKline - Hikma Pharmaceuticals - Jordanian Pharmaceutical Manufacturing Company (JPM) - Merck & Co - Novartis - Pfizer - Pharma International Company - Sanofi - United Pharmaceutical Manufacturers For more information visit http://www.researchandmarkets.com/research/5xfhgw/the About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
MRK: 63.36 (-0.27), GSK: 44.16 (-0.33), NVS: 81.34 (-0.60)
Saudi Arabia Pharmaceutical Market Overview 2015
M2 - Thu Sep 24, 6:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3rdslv/the) has announced the addition of the "The Pharmaceutical Market: Saudi Arabia" report to their offering. Saudi Arabia' s transition to an increasingly privatised and comprehensive healthcare system will drive the demand for both patented and generic drugs . The country is investing heavily in healthcare infrastructure and we expect this will be borne out in double-digit growth forecasts across our three headline indicators. Risk/Reward Rating: Saudi Arabia's composite score remained steady in Q4 at 55.6. This places the country to firth place out of the 30 markets in the region. Its score is propped up by the country's wealth and a sizeable population (exceeding 28mn). Furthermore, its forecast growth rate is high due to favourable public and private healthcare investments. The government is also in the process of creating more public-private health partnerships and encouraging private health insurance uptake, which should provide momentum for drug sales. Competitive Landscape: The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors. Company Profiles - SPIMACO - Saudi Arabian Japanese Pharmaceutical (SAJA) - TABUK Pharmaceutical Manufacturing - Jamjoom Pharma - GlaxoSmithKline - Novartis - Merck & Co - Pfizer - Sanofi - Hikma Pharmaceuticals Plc For more information visit http://www.researchandmarkets.com/research/3rdslv/the
MRK: 63.36 (-0.27), GSK: 44.16 (-0.33), NVS: 81.34 (-0.60)
Lower Respiratory Tract Infections Market Analysis 2015 - Global API Manufacturers and Phase III Pipeline Assessment
M2 - Thu Aug 06, 9:52AM CDT
Research and Markets (http://www.researchandmarkets.com/research/396bfs/lower_respiratory) has announced the addition of the "Lower Respiratory Tract Infections- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment" report to their offering. Lower Respiratory Tract Infections- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 provides comprehensive insights about phase III pipeline drugs and marketed drugs across the indication. A key objective of the report is to establish the understanding for API Manufacturers for marketed and Phase III pipeline drugs across the different countries and regions. While the leading brands, companies and chemicals are considered thoroughly, the report also provides details on the drug master filings across the US, Europe and Asia specifically China and India. The research, analysis also presents the global sales forecasts data till 2015. The report is also giving insight about the patent and exclusivity details of all the drugs across the indication. Reasons to buy - Evaluate the marketing status and exclusivity details of Lower Respiratory Tract Infections key products to exploit opportunities for generic drug development opportunities. - Identify and understand important and diverse types of therapeutics under Phase III development for Lower Respiratory Tract Infections. - Design effective counter-strategies to gain competitive advantage by identifying the key patent expiry details and exclusivity with respect to Lower Respiratory Tract Infections. - API intelligence over marketed drugs for Lower Respiratory Tract Infections and gaining primary intelligence over active ingredients manufacturers across the globe. - API intelligence over leading Phase III pipeline drugs. - Develop and designstrategies by identifying the API manufacturers for Phase III pipeline products to enhance and expand business potential and scope. - Understanding the scope of the Phase III Drugs with nil regulatory filings. - Understanding the chemical route of synthesis of approved drugs for Lower Respiratory Tract Infections. - Uncovering opportunities in the rapidly growing the US markets. Companies Mentioned - Merck & Co., Inc. - Dr. Reddy's Laboratories Limited - Corden Pharma International GmbH - Eli Lilly and Company - Genentech, Inc. - Arbor Pharmaceuticals, Inc. - Bayer AG - Bristol-Myers Squibb Company - Mayne Pharma Limited - Hospira, Inc. - B. Braun Medical Inc. - Bayer Inc. - Actavis, Inc. - Hikma Pharmaceuticals PLC - Sandoz Inc. - Mutual Pharmaceutical Company, Inc. - Par Pharmaceutical Companies, Inc. - GlaxoSmithKline plc - Covis Pharmaceuticals, Inc - Pfizer Inc. - Sanofi - sanofi-aventis U.S. LLC. - King Pharmaceuticals Ltd - Pharmacia & Upjohn, Inc. - AstraZeneca PLC - Astellas Pharma US, Inc. - Baxter Healthcare Corporation - Abraxis BioScience, Inc. - GlaxoSmithKline Inc. - Wyeth Pharmaceuticals, Inc. - GlaxoSmithKline LLC - Warner Chilcott Plc - Wockhardt USA LLC - Hoffmann-La Roche Inc. - Dr. Reddy's Laboratories Inc. For more information visit http://www.researchandmarkets.com/research/39...espiratory
ACT: 298.98 (-2.94), PFE: 34.98 (-0.21), LLY: 79.06 (-0.72), BMY: 59.29 (+0.61), GSK: 44.16 (-0.33), MRK: 63.36 (-0.27), AZN: 33.56 (-0.01)
United States General Anesthesia Drugs Market 2015 - Molecule, Route of Administration, Supply Chain & Competitive Analysis to 2020
PR Newswire Europe - Wed Aug 05, 11:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vr6xj9/u_s_general [http://www.researchandmarkets.com/research/vr6xj9/u_s_general]) has announced the addition of the "U.S. General Anesthesia Drugs Market by Molecule (Propofol, Benzodiazepines, ketamine(s(+) ketamine HCl), Methohexital Sodium), route of administration (Intravenous, Inhalational), Supply Chain (GPOs, Distributors), Competitive - Analysis Forecast to 2020 [http://www.researchandmarkets.com/research/vr6xj9/u_s_general)]" report to their offering.
ABT: 44.24 (-0.12), BAX: 47.95 (-0.06), AZN: 33.56 (-0.01)
Hikma Founder and Honorary Life President Samih Darwazah Passes Away
PR Newswire Europe - Mon May 18, 7:06AM CDT
LONDON, May 18, 2015 /PRNewswire/ --
Abortion Market Analysis 2014-2015 - Global API Manufacturers and Phase III Pipeline Assessment
M2 - Tue Jan 13, 9:54AM CST
Research and Markets (http://www.researchandmarkets.com/research/mf3fgc/abortion_market) has announced the addition of the "Abortion- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014" report to their offering. Abortion- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 provides comprehensive insights about phase III pipeline drugs and marketed drugs across the indication. A key objective of the report is to establish the understanding for API Manufacturers for marketed and Phase III pipeline drugs across the different countries and regions. While the leading brands, companies and chemicals are considered thoroughly, the report also provides details on the drug master filings across the US, Europe and Asia specifically China and India. The research, analysis also presents the global sales forecasts data till 2015. The report is also giving insight about the patent and exclusivity details of all the drugs across the indication. Key Topics Covered: - Indication Overview - Marketed Drugs Assessment - Marketed Details of Drugs by Application Type - Marketed Details of Drugs (NDA) by Marketing Status - Marketed Details of Drugs by Patent Expiration Timeline - The Active Pharmaceutical Ingredient (API) Manufacturers Assessment - The API Manufacturers by the United States Drug Master File (US DMF) Status - The API Manufacturers by the US DMF Status (Drug Specific) - The Active Pharmaceutical Ingredient (API) Manufacturers Assessment for Phase III Pipeline Drugs - The API Manufacturers by the US DMF Status (Drug Specific) - Drugs Market Data and Forecasted Sales Figures (2011-2015) - Marketed Drugs Information - Drugs Description - Route of Synthesis - Global Active Pharmaceutical Manufacturers - Approval Status - Patent and Exclusivity Details - Company Overview - Phase III Drugs Information - Phase III Drugs Description - The United States Drug Master Filings (US DMF) - Discontinued Drugs Information Companies Mentioned - Pharmacia Limited - Pfizer Inc. - Danco Laboratories, LLC - Hikma Pharmaceuticals PLC - Novartis Pharmaceuticals Corporation - APP Pharmaceuticals, Inc. - Solvay Pharma Inc. - Grifols, S.A. For more information visit http://www.researchandmarkets.com/research/mf...ion_market
PFE: 34.98 (-0.21), NVS: 81.34 (-0.60)
Hikma to Launch Colchicine 0.6mg Capsules
PR Newswire - Fri Jan 09, 5:10PM CST
Hikma Pharmaceuticals PLC ("Hikma"
(LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), the fast growing multinational pharmaceutical group, today notes that Takeda Pharmaceuticals U.S.A. Inc. ("Takeda" has been unsuccessful in appealing the decision by the United States District Court for the District of Delaware to deny Takeda's motion for a preliminary injunction in relation to the distribution of Hikma's colchicine 0.6mg capsules for the prophylaxis of gout flares in adults. The injunction, which was granted to Takeda on 9 October 2014, has been vacated.
Hikma Pharmaceuticals Announces it Received a Warning Letter from Federal Regulators Over Significant Issues Discovered at Portugal Plant, Parker Waichman LLP Comments
PRWeb - Thu Nov 13, 11:04AM CST
Parker Waichman LLP, a national law firm that has long been dedicated to protecting the rights of victims who have been injured by medications, comments on an October 24, 2014 Hikma Pharmaceuticals' announcement that the multinational pharmaceutical group received a Warning Letter from the U.S. Food and Drug Administration (FDA) concerning an inspection that took place at its Portugal manufacturing facility in March 2014.
Wound Management Technologies Appoints Ronald Goode and Jeffrey Lewis to the Board of Directors
Marketwired - Tue Oct 21, 7:30AM CDT
Wound Management Technologies, Inc. (OTCQB: WNDM), an emerging commercial stage company with its primary product, a patent-protected and FDA-cleared collagen product, CellerateRX(R), announces that the Company appointed Ronald Goode and Jeffrey Lewis to the Board of Directors.
Global Nerve Gas Auto-Injector Market Report 2016-2020 - Analysis, Technologies & Forecasts - Key Vendors: Baxter International, Hikma Pharmaceuticals, Hospira - Research and Markets
BusinessWire - Wed May 11, 9:30AM CDT
Research and Markets has announced the addition of the "Nerve Gas Auto-Injector Market" report to their offering.
BAX: 47.95 (-0.06)
Xellia Pharmaceuticals Expands US Production with Acquisition of Manufacturing Plant from Hikma Pharmaceuticals
BusinessWire - Wed Nov 25, 3:08AM CST
Xellia Pharmaceuticals ('Xellia'), a specialty pharmaceutical company focusing on providing important anti-infective treatments against serious and often life-threatening infections, has acquired manufacturing facilities in Bedford, Ohio from a wholly owned subsidiary of Hikma Pharmaceuticals PLC ('Hikma'). Financial details are not disclosed.
Global Biosimilars Market Report, 2015-2025 - The biosimilar market is projected to be worth USD 32 billion worldwide by 2025
PR Newswire Europe - Tue Nov 03, 11:11AM CST
Research and Markets (http://www.researchandmarkets.com/research/hcv3cc/global [http://www.researchandmarkets.com/research/hcv3cc/global]) has announced the addition of the "Global Biosimilars Market, 2015 - 2025" [http://www.researchandmarkets.com/research/hcv3cc/global] report to their offering.
BIIB: 316.81 (+3.43), UTHR: 126.92 (+1.30), CTIC: 0.35 (unch), CHRS: 30.51 (+0.37), JNJ: 119.92 (-0.80), NPSP: 45.97 (+0.01), IBIO: 0.66 (-0.01), EBS: 28.01 (+0.09), SLXP: 172.96 (+0.15), AMGN: 173.62 (-1.13), SPPI: 5.91 (-0.02), LLY: 79.06 (-0.72), GSK: 44.16 (-0.33), ANIK: 49.82 (+0.04), NVO: 46.88 (-0.16), BAX: 47.95 (-0.06), MRK: 63.36 (-0.27), NVS: 81.34 (-0.60)
Central Asia Business Daily Subscriptioon
M2 - Thu Oct 22, 3:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kmg769/central_asia) has announced the addition of the "Central Asia Business Daily " newsletter to their offering. The central Asia Business Daily, delivers all the business news of Central Asia companies/industries/economy that helps companies/investors to follow-up on new business opportunities of and among Central Asian countries such as Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan, and Uzbekistan and with rest of the world. The objective of this daily report is to comprehensively cover Central Asia business news daily and thereby help the investors in Central Asia and rest of the world to assess the investment trends and opportunities of Central Asia business. Key Features - Most-updated daily news coverage provided by the 24/7 news researchers at 3 global offices - Company news analysts with years of experience analyze business transactions and the investment trends every day for Central Asia to put together this Daily Report - Most of the available news resources comprehensively covered (including established news portals, reliable primary and secondary news sources, business media sites, company websites, press releases, and stock exchanges) - Original news source links provided for all news for further reference - For any incomplete news or information, assistance taken from the relevant officials/executives through e-mails/phone calls - This Daily Report is specifically designed to bring-out every day all the available news on the current business transactions, investment trends, business opportunities and helpful resources for pursuing Central Asian collaborations. Any other related query, analytical and research, is also furnished if needed Publication Frequency: Daily Key Topics Covered: Section 1: Business News of Each Central Asian Country Section 2: Business News among Central Asian Countries Section 3: International Business News with Central Asia Companies Mentioned - ATFBank JSC - Asian Development Bank - Asiana Airlines - Barqi Tojik - Beeline Uzbekistan LLC - Central Bank of Uzbekistan - Daewoo Group - Flynas Company LCC - GM Uzbekistan - Hikma Pharmaceuticals PL - INGO-Uzbekistan - Islamic Development Bank - KAZ Minerals PLC - Karachaganak Petroleum Operating B.V. - Kcell JSC - LG Electronics Inc. - Microsoft Kazakhstan - Nur Telecom - Pojazdy Szynowe PESA Bydgoszcz SA - Rio Tinto Group United Kingdom - Samruk-Kazyna National Welfare Fund JSC - Telecom Tajikistan - Tengizchevroil JSC - Thomson Reuters Corp. - Toyota Motor Corporation - Turkish Petroleum Corporation - Uzbekistan Airways - Uzbekneftegaz JSC - VimpelCom Ltd. - Vostok-geoldobycha OJSC For more information visit http://www.researchandmarkets.com/research/km...ntral_asia
VIP: 4.35 (unch), TM: 119.62 (+0.68), TRI: 41.61 (-0.27)
Basilea signs exclusive distribution agreement for Zevtera(r) (ceftobiprole medocaril) in the Middle East and North Africa with Hikma Pharmaceuticals LLC
GlobeNewswire - Thu Oct 15, 12:20AM CDT
-- Hikma to commercialize antibiotic Zevtera in the Middle East and North Africa (MENA) region
Jordan Pharmaceutical Market Study 2015
M2 - Fri Sep 25, 5:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5xfhgw/the) has announced the addition of the "The Pharmaceutical Market: Jordan" report to their offering. Overview Of The Pharmaceutical Market In Jordan: We expect that Jordan will continue to provide modest opportunities to research-based pharmaceutical manufacturers. In line with the authorities' efforts to expand healthcare insurance coverage , we envisage measures aiming to promote the use of cheaper generic medicines, in tandem with price-reduction strategies. Nevertheless, the expansion of government provision and the higher uptake of generic medicines will conspire to keep longer term growth steady , boosted by upward volume changes, with the patented drug market to continue to be supported by rising numbers of medical tourists. Risk/Reward Rating: Jordan's composite Pharmaceutical Risk/Reward Ratings score for Q1 remains unchanged in relation to the previous quarter. At 49.9 out of the maximum 100, Jordan is again ranked 10th, out of the 30 markets surveyed in the Middle East and Africa region. Jordan's rewards and risk scores remain evenly balanced, with both components standing firmly above the regional averages. Companies Mentioned - Dar al-Dawa - GlaxoSmithKline - Hikma Pharmaceuticals - Jordanian Pharmaceutical Manufacturing Company (JPM) - Merck & Co - Novartis - Pfizer - Pharma International Company - Sanofi - United Pharmaceutical Manufacturers For more information visit http://www.researchandmarkets.com/research/5xfhgw/the About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
MRK: 63.36 (-0.27), GSK: 44.16 (-0.33), NVS: 81.34 (-0.60)
Saudi Arabia Pharmaceutical Market Overview 2015
M2 - Thu Sep 24, 6:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3rdslv/the) has announced the addition of the "The Pharmaceutical Market: Saudi Arabia" report to their offering. Saudi Arabia' s transition to an increasingly privatised and comprehensive healthcare system will drive the demand for both patented and generic drugs . The country is investing heavily in healthcare infrastructure and we expect this will be borne out in double-digit growth forecasts across our three headline indicators. Risk/Reward Rating: Saudi Arabia's composite score remained steady in Q4 at 55.6. This places the country to firth place out of the 30 markets in the region. Its score is propped up by the country's wealth and a sizeable population (exceeding 28mn). Furthermore, its forecast growth rate is high due to favourable public and private healthcare investments. The government is also in the process of creating more public-private health partnerships and encouraging private health insurance uptake, which should provide momentum for drug sales. Competitive Landscape: The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors. Company Profiles - SPIMACO - Saudi Arabian Japanese Pharmaceutical (SAJA) - TABUK Pharmaceutical Manufacturing - Jamjoom Pharma - GlaxoSmithKline - Novartis - Merck & Co - Pfizer - Sanofi - Hikma Pharmaceuticals Plc For more information visit http://www.researchandmarkets.com/research/3rdslv/the
MRK: 63.36 (-0.27), GSK: 44.16 (-0.33), NVS: 81.34 (-0.60)
Lower Respiratory Tract Infections Market Analysis 2015 - Global API Manufacturers and Phase III Pipeline Assessment
M2 - Thu Aug 06, 9:52AM CDT
Research and Markets (http://www.researchandmarkets.com/research/396bfs/lower_respiratory) has announced the addition of the "Lower Respiratory Tract Infections- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment" report to their offering. Lower Respiratory Tract Infections- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 provides comprehensive insights about phase III pipeline drugs and marketed drugs across the indication. A key objective of the report is to establish the understanding for API Manufacturers for marketed and Phase III pipeline drugs across the different countries and regions. While the leading brands, companies and chemicals are considered thoroughly, the report also provides details on the drug master filings across the US, Europe and Asia specifically China and India. The research, analysis also presents the global sales forecasts data till 2015. The report is also giving insight about the patent and exclusivity details of all the drugs across the indication. Reasons to buy - Evaluate the marketing status and exclusivity details of Lower Respiratory Tract Infections key products to exploit opportunities for generic drug development opportunities. - Identify and understand important and diverse types of therapeutics under Phase III development for Lower Respiratory Tract Infections. - Design effective counter-strategies to gain competitive advantage by identifying the key patent expiry details and exclusivity with respect to Lower Respiratory Tract Infections. - API intelligence over marketed drugs for Lower Respiratory Tract Infections and gaining primary intelligence over active ingredients manufacturers across the globe. - API intelligence over leading Phase III pipeline drugs. - Develop and designstrategies by identifying the API manufacturers for Phase III pipeline products to enhance and expand business potential and scope. - Understanding the scope of the Phase III Drugs with nil regulatory filings. - Understanding the chemical route of synthesis of approved drugs for Lower Respiratory Tract Infections. - Uncovering opportunities in the rapidly growing the US markets. Companies Mentioned - Merck & Co., Inc. - Dr. Reddy's Laboratories Limited - Corden Pharma International GmbH - Eli Lilly and Company - Genentech, Inc. - Arbor Pharmaceuticals, Inc. - Bayer AG - Bristol-Myers Squibb Company - Mayne Pharma Limited - Hospira, Inc. - B. Braun Medical Inc. - Bayer Inc. - Actavis, Inc. - Hikma Pharmaceuticals PLC - Sandoz Inc. - Mutual Pharmaceutical Company, Inc. - Par Pharmaceutical Companies, Inc. - GlaxoSmithKline plc - Covis Pharmaceuticals, Inc - Pfizer Inc. - Sanofi - sanofi-aventis U.S. LLC. - King Pharmaceuticals Ltd - Pharmacia & Upjohn, Inc. - AstraZeneca PLC - Astellas Pharma US, Inc. - Baxter Healthcare Corporation - Abraxis BioScience, Inc. - GlaxoSmithKline Inc. - Wyeth Pharmaceuticals, Inc. - GlaxoSmithKline LLC - Warner Chilcott Plc - Wockhardt USA LLC - Hoffmann-La Roche Inc. - Dr. Reddy's Laboratories Inc. For more information visit http://www.researchandmarkets.com/research/39...espiratory
ACT: 298.98 (-2.94), PFE: 34.98 (-0.21), LLY: 79.06 (-0.72), BMY: 59.29 (+0.61), GSK: 44.16 (-0.33), MRK: 63.36 (-0.27), AZN: 33.56 (-0.01)
United States General Anesthesia Drugs Market 2015 - Molecule, Route of Administration, Supply Chain & Competitive Analysis to 2020
PR Newswire Europe - Wed Aug 05, 11:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vr6xj9/u_s_general [http://www.researchandmarkets.com/research/vr6xj9/u_s_general]) has announced the addition of the "U.S. General Anesthesia Drugs Market by Molecule (Propofol, Benzodiazepines, ketamine(s(+) ketamine HCl), Methohexital Sodium), route of administration (Intravenous, Inhalational), Supply Chain (GPOs, Distributors), Competitive - Analysis Forecast to 2020 [http://www.researchandmarkets.com/research/vr6xj9/u_s_general)]" report to their offering.
ABT: 44.24 (-0.12), BAX: 47.95 (-0.06), AZN: 33.56 (-0.01)
Hikma Founder and Honorary Life President Samih Darwazah Passes Away
PR Newswire Europe - Mon May 18, 7:06AM CDT
LONDON, May 18, 2015 /PRNewswire/ --
Abortion Market Analysis 2014-2015 - Global API Manufacturers and Phase III Pipeline Assessment
M2 - Tue Jan 13, 9:54AM CST
Research and Markets (http://www.researchandmarkets.com/research/mf3fgc/abortion_market) has announced the addition of the "Abortion- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014" report to their offering. Abortion- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 provides comprehensive insights about phase III pipeline drugs and marketed drugs across the indication. A key objective of the report is to establish the understanding for API Manufacturers for marketed and Phase III pipeline drugs across the different countries and regions. While the leading brands, companies and chemicals are considered thoroughly, the report also provides details on the drug master filings across the US, Europe and Asia specifically China and India. The research, analysis also presents the global sales forecasts data till 2015. The report is also giving insight about the patent and exclusivity details of all the drugs across the indication. Key Topics Covered: - Indication Overview - Marketed Drugs Assessment - Marketed Details of Drugs by Application Type - Marketed Details of Drugs (NDA) by Marketing Status - Marketed Details of Drugs by Patent Expiration Timeline - The Active Pharmaceutical Ingredient (API) Manufacturers Assessment - The API Manufacturers by the United States Drug Master File (US DMF) Status - The API Manufacturers by the US DMF Status (Drug Specific) - The Active Pharmaceutical Ingredient (API) Manufacturers Assessment for Phase III Pipeline Drugs - The API Manufacturers by the US DMF Status (Drug Specific) - Drugs Market Data and Forecasted Sales Figures (2011-2015) - Marketed Drugs Information - Drugs Description - Route of Synthesis - Global Active Pharmaceutical Manufacturers - Approval Status - Patent and Exclusivity Details - Company Overview - Phase III Drugs Information - Phase III Drugs Description - The United States Drug Master Filings (US DMF) - Discontinued Drugs Information Companies Mentioned - Pharmacia Limited - Pfizer Inc. - Danco Laboratories, LLC - Hikma Pharmaceuticals PLC - Novartis Pharmaceuticals Corporation - APP Pharmaceuticals, Inc. - Solvay Pharma Inc. - Grifols, S.A. For more information visit http://www.researchandmarkets.com/research/mf...ion_market
PFE: 34.98 (-0.21), NVS: 81.34 (-0.60)
Hikma to Launch Colchicine 0.6mg Capsules
PR Newswire - Fri Jan 09, 5:10PM CST
Hikma Pharmaceuticals PLC ("Hikma"
(LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), the fast growing multinational pharmaceutical group, today notes that Takeda Pharmaceuticals U.S.A. Inc. ("Takeda" has been unsuccessful in appealing the decision by the United States District Court for the District of Delaware to deny Takeda's motion for a preliminary injunction in relation to the distribution of Hikma's colchicine 0.6mg capsules for the prophylaxis of gout flares in adults. The injunction, which was granted to Takeda on 9 October 2014, has been vacated. Hikma Pharmaceuticals Announces it Received a Warning Letter from Federal Regulators Over Significant Issues Discovered at Portugal Plant, Parker Waichman LLP Comments
PRWeb - Thu Nov 13, 11:04AM CST
Parker Waichman LLP, a national law firm that has long been dedicated to protecting the rights of victims who have been injured by medications, comments on an October 24, 2014 Hikma Pharmaceuticals' announcement that the multinational pharmaceutical group received a Warning Letter from the U.S. Food and Drug Administration (FDA) concerning an inspection that took place at its Portugal manufacturing facility in March 2014.
Wound Management Technologies Appoints Ronald Goode and Jeffrey Lewis to the Board of Directors
Marketwired - Tue Oct 21, 7:30AM CDT
Wound Management Technologies, Inc. (OTCQB: WNDM), an emerging commercial stage company with its primary product, a patent-protected and FDA-cleared collagen product, CellerateRX(R), announces that the Company appointed Ronald Goode and Jeffrey Lewis to the Board of Directors.
(0)
(0)Scroll down for more posts ▼